<DOC>
	<DOCNO>NCT00449553</DOCNO>
	<brief_summary>The purpose study ass change glycosylated hemoglobin , fast blood lipid genetic polymorphism 's peroxisomal proliferator activate receptor -- gamma receptor 6 month pioglitazone , daily ( QD ) , treatment .</brief_summary>
	<brief_title>Observational Study Assess Glycosylated Hemoglobin Changes After 6 Months Treatment With Pioglitazone .</brief_title>
	<detailed_description>The metabolic control type 2 diabetes mellitus measure mean glycosylated hemoglobin . A low value glycosylated hemoglobin indicates good metabolic control , show associate well prognosis regard diabetic complication . Type 2 diabetes disease profound genetic component . Peroxisome proliferator-activated receptor gamma transcription factor implicate adipocyte differentiation , lipid glucose metabolism . Peroxisome proliferator-activated receptor alfa transcription factor implicate lipid oxidation gluconeogenesis present liver , kidney , heart , skeletal muscle adipose tissue . Pioglitazone thiazolidinedione target nuclear peroxisomal proliferator activate receptor , member super family ligand activate transcription factor . Specifically , thiazolidinediones bind peroxisome proliferator-activated receptor gamma affect transcription factor influence expression gene responsible production protein important carbohydrate lipoprotein metabolism . These include increase glucose transporter 1 4 result enhanced peripheral glucose utilization fat skeletal muscle . This pharmacoepidemiological study evaluate whether individual genotype patient influence efficacy pioglitazone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Fulfills requirement treatment pioglitazone . Willing start treatment pioglitazone . Has previously participate study . Is currently take take oral antidiabetic medication sulfonylurea metformin within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>